Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis

Mia Shapiro(Harvard University), Jason S. Gold(Memorial Sloan Kettering Cancer Center), Bisweswar Nandi(Brigham and Women's Hospital), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Gabriel González(Arc Research Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Hiroshi Mashimo(VA Boston Healthcare System), Rao Prabhala, Natasha Y. Frank(Brigham and Women's Hospital)
OncoImmunology
December 7, 2016
10.1080/2162402x.2016.1261776
Cited by 17

Related Papers

Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
|New England Journal of Medicine|2009|1.4k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k